Dr. Fraser completed his MD/PhD in the Department of Physiology and Biophysics at the University of Calgary, Alberta, Canada. He was the recipient of a Canadian Institutes of Health Research Strategic Training Fellowship and several prestigious International Research Awards from the American Academy of Pediatrics and the Society for Pediatric Research.
Dr. Fraser is a Professor and Clinician Scientist in Pediatric Critical Care/Trauma Medicine at Western University in London, Ontario, Canada. He is a Fellow of the Royal College of Physicians and Surgeons of Canada. Dr. Fraser is the Director of the Translational Research Centre, a human tissue biobank operating continuously for the past 15 years. He has received multiple Research Innovation Awards and he has filed and executed numerous patents. Dr. Fraser is a Co-Founder and Chief Medical Officer of NeuroLytixs, Inc., a diagnostics-based biotech company.
Dr. Fraser’s research is focused on identifying signaling pathways and diagnostics/prognostic biomarkers for acquired brain injury, severe sepsis and COVID-19. He has profiled Long-COVID patients for changes in their proteome, with specific emphasis on understanding the immune response. He currently leads two International Multicentered Long-COVID Research Programs, “LC-Optimize” (Identification of Long-COVID Sub-Phenotypes to Optimize Patient Outcomes) and “LC-Statistic” (Sudden Death Associated with Post-COVID Condition).
